Concepedia

Publication | Open Access

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

DOIFull Paper Access

36

Citations

26

References

2020

Year

Sang Eun Won, Hyo Jung Park, Sangil Byun, Junhee Pyo, Jae‐Hoon Kim, Chang‐Min Choi, Jae Cheol Lee, Dae Ho Lee, Sang‐We Kim, Shinkyo Yoon,
OncoImmunology

Abstract

PsP occurred in 3.7% of NSCLC patients under ICI treatment. Based on iRECIST scheme, PsP and TBP may be associated with survival benefit.

References

YearCitations

Page 1